Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Treasury Shares (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Treasury Shares for 12 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares changed 0.0% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $4.0 million for FY2025, 0.0% changed from the prior year.
  • Treasury Shares hit $4522.0 in Q4 2025 for Vistagen Therapeutics, roughly flat from $4522.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $135665.0 in Q1 2021 to a low of $4522.0 in Q1 2022.
  • Historically, Treasury Shares has averaged $52837.8 across 5 years, with a median of $4522.0 in 2022.
  • Biggest five-year swings in Treasury Shares: changed 0.0% in 2021 and later dropped 0.0% in 2023.
  • Year by year, Treasury Shares stood at $4.0 million in 2021, then changed by 0.0% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then dropped by 0.0% to $4.0 million in 2024, then changed by 0.0% to $4.0 million in 2025.
  • Business Quant data shows Treasury Shares for VTGN at $4.0 million in Q4 2025, $4.0 million in Q3 2025, and $4.0 million in Q2 2025.